Blood test may let cancer patients take safe breaks from immunotherapy

NCT ID NCT07689812

First seen Jul 08, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunotherapy or intermittent therapy guided by the blood test. The goal is to see if the intermittent approach provides similar survival while potentially reducing side effects and treatment time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Signatera blood test (ctDNA monitoring)
What this could lead to
If successful, this approach could allow many patients to take breaks from immunotherapy without harming survival, reducing side effects and treatment burden.
What could go wrong
This is an early-stage concept; the strategy may not provide the same survival benefit as continuous therapy, and some patients might need to restart treatment sooner than expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.